Tisotumab Vedotin Shows Superior Efficacy in Recurrent Cervical Cancer Treatment, reveals research
Researchers in a recent study have found that tisotumab vedotin, a novel therapy, significantly enhances survival outcomes in patients with recurrent or metastatic cervical cancer who have progressed after initial treatments. This study was published in The New England Journal Of Medicine. Ignace Vergote and colleagues conducted a phase 3, multinational trial to assess the efficacy of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. The study aimed to compare its effectiveness against standard chemotherapy options, offering new hope for patients facing limited treatment alternatives.
The trial enrolled 502 patients who were randomly assigned to receive either tisotumab vedotin monotherapy or a choice of chemotherapy agents (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary endpoint was overall survival, with secondary endpoints including progression-free survival and objective response rate.
The study’s findings were as follows:
• Patients treated with tisotumab vedotin had a median overall survival of 11.5 months, compared to 9.5 months in the chemotherapy group—a 30% reduction in the risk of death (HR 0.70, 95% CI 0.54-0.89, P=0.004).
• Progression-free survival was also significantly longer with tisotumab vedotin (4.2 months vs. 2.9 months, HR 0.67, 95% CI 0.54-0.82, P<0.001).
• The confirmed objective response rate was 17.8% with tisotumab vedotin versus 5.2% with chemotherapy (OR 4.0, 95% CI 2.1-7.6, P<0.001).
• Adverse events were common in both groups, occurring in over 98% of patients, with grade 3 or greater events reported in 52.0% of the tisotumab vedotin group and 62.3% of the chemotherapy group.
• Approximately 14.8% of patients discontinued tisotumab vedotin due to treatment-related toxic effects.
In conclusion, the study highlights the superior efficacy of tisotumab vedotin over standard chemotherapy in treating recurrent cervical cancer. The findings underscore its potential as a valuable treatment option in later lines of therapy, offering improved survival outcomes and a higher objective response rate.
Reference:
Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., Lee, J.-Y., Banerjee, S., Maluf, F. C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso, L., Woelber, L., Westermann, A., Covens, A., Hasegawa, K., Kim, B.-G., Raimondo, M., … Slomovitz, B. M. (2024). Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. The New England Journal of Medicine, 391(1), 44–55. https://doi.org/10.1056/nejmoa2313811
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd